Clovis Oncology Inc (NASDAQ:CLVS)

7.34
BATS BZX Real-Time Price
As of 10:23am ET
 +0.66 / +9.88%
Today’s Change
3.62
Today|||52-Week Range
11.63
+52.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$556.4M

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Individual stakeholders4.84%
Mutual fund holders34.51%
Other institutional29.11%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial Officer & Executive Vice President
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Paul Edward GrossSecretary, Executive VP & General Counsel